Srv Pharma Private Limited
Pharmaceutical company manufacturing, selling, and distributing drugs and enzymes since 2012.
2012 | Delhi (India) | Active
Srv Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 12 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
- Revenue Growth 0.36%
- Profit Growth 5.00%
- Ebitda -7.19%
- Net Worth 4.98%
- Total Assets 8.76%
About Srv Pharma
Srv Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 November 2012 and has a history of 12 years and two months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.00 M.
Rishabh Bansal and Vipin Bansal serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U85100DL2012PTC245514
- Company No.
245514
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Nov 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Pharma
Who are the key members and board of directors at Srv Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rishabh Bansal  | Director | 30-Nov-2012 | Current |
| Vipin Bansal | Director | 30-Nov-2012 | Current |
Financial Performance of Srv Pharma.
Srv Pharma Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 0.36% increase. The company also saw a slight improvement in profitability, with a 5% increase in profit. The company's net worth moved up by a moderate rise of 4.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Srv Pharma?
In 2019, Srv Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charan Laboratories Private LimitedRishabh Bansal and Vipin Bansal are mutual person
Charges (Loans)
Open Charges
₹1.00 M
Satisfied Charges
₹0
Charges Breakdown by Lending Institutions
- Others : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Oct 2016 | Others | ₹1.00 M | Open |
How Many Employees Work at Srv Pharma?
Unlock and access historical data on people associated with Srv Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Srv Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Srv Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.